166 related articles for article (PubMed ID: 7843948)
1. Sumatriptan in acute migraine using a novel cartridge system self-injector. United Kingdom Study Group.
Gross ML; Kay J; Turner AM; Hallett K; Cleal AL; Hassani H
Headache; 1994; 34(10):559-63. PubMed ID: 7843948
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy of subcutaneous sumatriptan using a novel self-injector.
Gross ML; Kay J; Turner AM; Jewsbury J; Cleal AL
Headache; 1995; 35(10):601-6. PubMed ID: 8550361
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).
Cady RK; McAllister PJ; Spierings EL; Messina J; Carothers J; Djupesland PG; Mahmoud RA
Headache; 2015 Jan; 55(1):88-100. PubMed ID: 25355310
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults.
Wendt J; Cady R; Singer R; Peters K; Webster C; Kori S; Byrd S
Clin Ther; 2006 Apr; 28(4):517-26. PubMed ID: 16750463
[TBL] [Abstract][Full Text] [Related]
5. An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan.
Landy SH; Tepper SJ; Wein T; Schweizer E; Ramos E
Headache; 2013 Jan; 53(1):118-125. PubMed ID: 23148799
[TBL] [Abstract][Full Text] [Related]
6. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.
Winner P; Rothner AD; Wooten JD; Webster C; Ames M
Headache; 2006 Feb; 46(2):212-22. PubMed ID: 16492230
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. Early-Morning Migraine Sumatriptan Study Group.
Bousser MG; D'Allens H; Richard A
J Intern Med; 1993 Aug; 234(2):211-6. PubMed ID: 8393474
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache.
Cull RE; Price WH; Dunbar A
J Neurol Neurosurg Psychiatry; 1997 May; 62(5):490-5. PubMed ID: 9153607
[TBL] [Abstract][Full Text] [Related]
9. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS
Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814
[TBL] [Abstract][Full Text] [Related]
10. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. The Sumatriptan Auto-Injector Study Group.
Eur Neurol; 1991; 31(5):323-31. PubMed ID: 1653140
[TBL] [Abstract][Full Text] [Related]
11. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J
Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents.
Winner P; Rothner AD; Saper J; Nett R; Asgharnejad M; Laurenza A; Austin R; Peykamian M
Pediatrics; 2000 Nov; 106(5):989-97. PubMed ID: 11061765
[TBL] [Abstract][Full Text] [Related]
13. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine.
Winner P; Ricalde O; Le Force B; Saper J; Margul B
Arch Neurol; 1996 Feb; 53(2):180-4. PubMed ID: 8639069
[TBL] [Abstract][Full Text] [Related]
14. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
[TBL] [Abstract][Full Text] [Related]
15. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study.
Tepper SJ; Cady R; Dodick D; Freitag FG; Hutchinson SL; Twomey C; Kuhn TA
Headache; 2006 Jan; 46(1):115-24. PubMed ID: 16412159
[TBL] [Abstract][Full Text] [Related]
16. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study.
Akpunonu BE; Mutgi AB; Federman DJ; Volinsky FG; Brickman K; Davis RL; Gilbert C; Asgharnejad M
Ann Emerg Med; 1995 Apr; 25(4):464-9. PubMed ID: 7710149
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. French Migraine Network Bordeaux-Lyon-Grenoble.
Henry P; d'Allens H
Headache; 1993 Sep; 33(8):432-5. PubMed ID: 8262783
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of sumatriptan injection for the treatment of morning migraine: two multicenter, prospective, randomized, double-blind, controlled studies in adults.
Winner P; Adelman J; Aurora S; Lener ME; Ames M
Clin Ther; 2006 Oct; 28(10):1582-91. PubMed ID: 17157114
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study.
Carpay J; Schoenen J; Ahmad F; Kinrade F; Boswell D
Clin Ther; 2004 Feb; 26(2):214-23. PubMed ID: 15038944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
